Cargando…

A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma

Temozolomide is an oral alkylating agent that readily crosses the blood–brain barrier and has activity in patients with advanced melanoma. Carboplatin is a convenient outpatient treatment that also has activity in patients with melanoma. The purpose of this study was to assess the safety of a combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strauss, S J, Marples, M, Napier, M P, Meyer, T, Boxall, J, Rustin, G J S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394438/ https://www.ncbi.nlm.nih.gov/pubmed/14612900 http://dx.doi.org/10.1038/sj.bjc.6601414

Ejemplares similares

Phase I-II study of carboplatin vincristine methotrexate and bleomycin (COMB) in carcinoma of the cervix.
por: Rustin, G. J., et al.
Publicado: (1988)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
por: Kefford, R F, et al.
Publicado: (2009)

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
por: Azzabi, A, et al.
Publicado: (2005)

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
por: Rangwala, Reshma, et al.
Publicado: (2014)

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
por: Middleton, M. R., et al.
Publicado: (1998)

Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours
por: Harries, M, et al.
Publicado: (2004)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
por: Newlands, E. S., et al.
Publicado: (1992)

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma
por: van der Westhuizen, Andre, et al.
Publicado: (2020)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site
por: Piga, A, et al.
Publicado: (2004)

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
por: Larkin, J M G, et al.
Publicado: (2007)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Haematological toxicity of carboplatin in rats.
por: Siddik, Z. H., et al.
Publicado: (1987)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

A phase I and pharmacokinetic study of indisulam in combination with carboplatin
por: Dittrich, C, et al.
Publicado: (2007)

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
por: Rigg, A., et al.
Publicado: (1997)

Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
por: Hong, David S., et al.
Publicado: (2015)

A Phase I Study of High-Dose Calcitriol in Combination with Temozolomide for Patients with Metastatic Melanoma
por: Pettijohn, Erin, et al.
Publicado: (2014)

High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
por: Lyttelton, M. P., et al.
Publicado: (1998)

A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
por: McClay, E. F., et al.
Publicado: (1993)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Temozolomide for the treatment of metastatic melanoma
por: Quirbt, I., et al.
Publicado: (2007)

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours
por: Gelderblom, H., et al.
Publicado: (2020)

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
por: Kerr, D. J., et al.
Publicado: (1989)

Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
por: Shen, Xinglei, et al.
Publicado: (2011)

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
por: Lassen, U, et al.
Publicado: (2010)

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.
por: Estlin, E. J., et al.
Publicado: (1998)

Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours
por: Napier, M P, et al.
Publicado: (2000)

Phase I trial of elactocin.
por: Newlands, E. S., et al.
Publicado: (1996)

Role of tumour markers in monitoring epithelial ovarian cancer
por: Meyer, T, et al.
Publicado: (2000)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
por: Millward, M, et al.
Publicado: (2013)

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
por: Glasspool, R M, et al.
Publicado: (2014)

Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies.
por: O'Reilly, S. M., et al.
Publicado: (1993)

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
por: Tawbi, H A, et al.
Publicado: (2011)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g5805f58aelemr4bipg838iuo6